Session Synopsis: Precision Medicine (PM) leaders will discuss issues and lessons learned implementing PM programs as well as opportunities for community oncology practices. Topics include: requirements for creating a precision medicine program (personnel, supports; working with sequencing labs;interpreting results;and tools needed to scale and bring genomic-guided therapies to physicians and patients). A presentation of the PrecisionPlan™ oncology workbench to facilitate patient-specific genomic-guided treatment plans at point-of-care in real-time will support the discussion.
Session Chair Profile
Ph.D., Co-founder and Chief Scientific Officer, Viviphi Ltd.
Dr. Ashbury joined Viviphi as a founding member in 2015 to develop a first-of-its-kind comprehensive clinical pathway and precision medicine planning platform. He is responsible for developing and maintaining all clinical content, including standard of care and genomic-science knowledge identification and codification, and designing and implementing treatment strategy rules that underpin the ViviphiTM platform. Dr. Ashbury has mentored oncology practices and networks worldwide to define quality metrics based on current evidence to establish practice accountability, reporting and quality improvement.He is a member of the American Society of Clinical Oncology; board member for the Multi-National Association of Supportive Care in Cancer (MASCC); Chair of the Guidelines Committee, MASCC; member of the University of Swinburne Industry Research Advisory Committee; and Editor-in-Chief of Supportive Care in Cancer.He graduated with honors from the University of Toronto (bachelor’s), Queen’s University (master’s), and York University (doctorate).
PharmD, Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Dr Howard McLeod is chair of the Department of Individualized Cancer Management and a State of Florida Cancer Research Endowed Chair. He is a Professor at the University of South Florida and a 1000 Talent Scholar of China. Dr McLeod is a recent member of the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Dr McLeod is vice chair for Pharmacogenomics for NCI ALLIANCE clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr McLeod is an active entrepreneur, serving on the Board of Directors, Scientific Advisory Board, and as a domain expert consultant to publically traded and privately held companies. He has also founded both for-profit and non- profit companies in the USA and China. Howard has published over 500 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.